Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Recommendation of “Hold” by Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been assigned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $8.00.

A number of equities analysts have recently issued reports on IVVD shares. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Invivyd in a report on Monday. Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research report on Tuesday, June 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th.

Invivyd Stock Performance

Shares of Invivyd stock opened at $0.97 on Friday. The firm’s 50-day simple moving average is $1.29 and its 200-day simple moving average is $1.73. Invivyd has a twelve month low of $0.48 and a twelve month high of $3.07. The firm has a market cap of $285.74 million, a P/E ratio of -3.13 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The business had revenue of $13.74 million during the quarter, compared to analyst estimates of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. On average, equities analysts forecast that Invivyd will post -0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Invivyd

Several large investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in Invivyd by 152.9% during the 1st quarter. Bank of America Corp DE now owns 962,386 shares of the company’s stock valued at $1,251,000 after purchasing an additional 581,782 shares during the last quarter. Stempoint Capital LP grew its stake in Invivyd by 89.4% during the first quarter. Stempoint Capital LP now owns 1,874,546 shares of the company’s stock worth $2,437,000 after buying an additional 884,724 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Invivyd by 1.7% during the first quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock worth $42,857,000 after buying an additional 551,188 shares in the last quarter. Eversept Partners LP increased its holdings in shares of Invivyd by 6.4% during the first quarter. Eversept Partners LP now owns 2,276,349 shares of the company’s stock worth $2,959,000 after buying an additional 136,219 shares in the last quarter. Finally, SummitTX Capital L.P. bought a new position in shares of Invivyd in the first quarter valued at approximately $37,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.